We’re joined by Chris Bardon, Managing Partner at MPM BioImpact — a Harvard-trained physician and biotech investor with more than 20 years of experience in the field — and Elaine Hamm, scientist-turned-operator, Executive in Residence at Tulane School of Medicine, Executive Director of the Alliance of Artificial Intelligence in Healthcare, and a portfolio manager in biopharma. Together we dig into the forces shaping biotech and life sciences today.
In Today's Episode We Discuss:
- Is the 2020 Biotech Bubble Hangover Finally Ending?
- How excessive funding led to the rise of low-quality biotech companies
- The reality behind AI in life sciences: true innovation versus marketing hype
- China’s transformation from contract research provider to global pharma competitor
- The overlooked risk of talent migration in the biotech industry
- How “platform company” narratives can distract from real value
- The biggest deal-breaker for investors: defensive leadership
- Why Intellectual Honesty Separates Winners from Losers
- The Hardest Decisions in Biotech Leadership
- Why lean, resourceful companies are best positioned to succeed today
Need the life-sciences signal but short on time?
Get a free quarterly briefing: four pages on what life-sciences operators are actually saying about Biosecure, AI hype vs. substance, and the $50,000 cell-therapy question. Ten minutes, in your inbox.
